Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus Metformin for weight and metabolic parameters in overweight patients on atypical antipsychotics
IRCT20120215009014N538Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in schizophrenia, bipolar disorder (BD) and Overweight comparing Empagliflozin with Metformin (2 arms). Primary endpoints: Change in body weight and Change in metabolic parameters. Started Jan 2025; status: completed.
02
Drugs
empagliflozinmetformin
03
Conditions
schizophreniabipolar disorder (BD)Overweight
Beyond the preview
Go deeper on IRCT20120215009014N538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N538.